Adam Laponis Sells 5,886 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CFO Adam Laponis sold 5,886 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the completion of the sale, the chief financial officer now directly owns 110,096 shares of the company’s stock, valued at $4,762,752.96. This represents a 5.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Adam Laponis also recently made the following trade(s):

• On Wednesday, November 6th, Adam Laponis sold 4,160 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total value of $185,536.00.

Twist Bioscience Stock Up 6.4 %

Twist Bioscience stock opened at $45.48 on Thursday. The business has a 50-day simple moving average of $46.42 and a 200 day simple moving average of $46.33. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The stock has a market cap of $2.70 billion, a price-to-earnings ratio of -12.63 and a beta of 1.85.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds have recently added to or reduced their stakes in the company. Avanza Fonder AB bought a new stake in Twist Bioscience during the fourth quarter worth about $1,059,000. Principal Financial Group Inc. lifted its stake in Twist Bioscience by 67.5% during the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock worth $9,301,000 after purchasing an additional 82,953 shares during the last quarter. Oddo BHF Asset Management Sas bought a new stake in Twist Bioscience during the third quarter worth about $3,302,000. Beaird Harris Wealth Management LLC bought a new stake in Twist Bioscience during the third quarter worth about $95,000. Finally, Franklin Resources Inc. lifted its stake in Twist Bioscience by 3.4% during the third quarter. Franklin Resources Inc. now owns 252,064 shares of the company’s stock worth $11,756,000 after purchasing an additional 8,308 shares during the last quarter.

Analyst Upgrades and Downgrades

TWST has been the subject of several recent research reports. Scotiabank lifted their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. TD Cowen reiterated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research initiated coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Barclays reduced their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Finally, Robert W. Baird lifted their price target on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.